Penumbra (PEN) Stock: Buy, Sell, or Hold?
PEN - Penumbra, Inc.
$317.73
-0.05 (-0.02%)
▼
5d:
-1.06%
30d:
-2.71%
90d:
-0.19%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When PEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: PEN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: PEN shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$298.53
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$185.36
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PEN is currently trading at $317.73, which is considered oversold relative to its 30-day fair value range of $320.81 to $326.13. The stock's valuation (Forward PE: 51.8) is in line with its historical norms (55.8). Remarkably, the market is currently pricing in an annual earnings decline of 2.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, PEN is in a downtrend. The price is currently testing key support at $317.58. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 48/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $361.83 (+13.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PEN is in a downtrend. The price is currently testing key support at $317.58. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 48/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $361.83 (+13.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$320.81 -
$326.13
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
81.5%
Protect Your Profits
Holding PEN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (48/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($361.83)
- WARNING: Composite score 51/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$320.81 -
$326.13
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$5.10
(1.6%)
Support & Resistance Levels
Support Level
$317.59
Resistance Level
$325.00
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
51.82
Wall Street Target
$361.83
(+13.9%)
Revenue Growth (YoY)
14.9%
Earnings Growth (YoY)
-23.5%
Profit Margin
10.7%
Valuation Discount vs History
-2.5% cheaper
PE vs Historical
51.8 vs 55.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.5%
(market-implied from PE analysis)
1-Year Target
$309.79
(-3%)
2-Year Target
$302.04
(-5%)
3-Year Target
$294.49
(-7%)
3-Yr Target (if PE normalizes)
(PE: 52→56)
$317.13
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 51.8, Growth: 28.1%)
$667.60
(+110%)
Base:
(SPY PE: 20.2, Growth: 28.1%)
$259.87
(-18%)
Bear:
(PE: 17.1, Growth: 28.1%)
$220.89
(-31%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (56x PE), but valuation improves significantly next year (52x PE) as earnings recover.
Forward PE: 55.56 | Forward EPS (Implied): $5.72
Bull Case
$383.66
(+21%)
Analyst growth 15.0%, PE expands to 58.3
Base Case
$317.73
(0%)
Market implied 0.0%, PE stable at 55.6
Bear Case
$243.06
(-24%)
Severe decline -15.0%, PE contracts to 50.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 51.8 to 55.8
Stabilization Target:
$342.16
(+7.7%)
PE Expansion Potential:
+7.7%
Share & Embed Analysis
Last updated: September 12, 2026 10:50 AM ET
Data refreshes hourly during market hours. Next update: 11:50 AM
Data refreshes hourly during market hours. Next update: 11:50 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Harpreet Grewal
SELL
100 shares
2026-04-02
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 40 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 44 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 56 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 41 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 41 HOLD |
Advanced PEN Option Strategies
Professional options setups generated by AI based on today's PEN price and gamma walls.
